New ointment could tame HHT nosebleeds
NCT ID NCT07667413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new nasal ointment called TOR-582, which contains sirolimus, in 27 adults with hereditary hemorrhagic telangiectasia (HHT) who have frequent nosebleeds. Participants apply the ointment inside their nostrils twice daily for 12 weeks, with different strengths tested to find the safest dose. The goal is to see if the treatment is safe enough to study further, potentially offering a less invasive way to manage nosebleeds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus ointment (TOR-582)
What this could lead to
If this works, it could lead to a new, non-invasive treatment to reduce nosebleeds in people with HHT, improving daily life and reducing the need for medical procedures.
What could go wrong
This is a very early phase 1 trial with only 27 participants, focused on safety and dosing. It may not show clear benefit, and side effects or lack of effectiveness could prevent further development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact